INmune Bio/INMB

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About INmune Bio

INmune Bio Inc. is a clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. It has two therapeutic platforms: a Dominant-Negative Tumor Necrosis Factor Platform (DN-TNF, XPro, XPro1595 or pegipanermin) and a Natural Killer (NK or INKmune) platform. The DN-TNF product platform utilizes dominant-negative technology to selectively neutralize soluble TNF, a key driver of innate immune dysfunction and a mechanistic driver of many diseases. DN-TNF product candidates are in clinical trials to determine if they can treat cancer (INB03) Mild Alzheimer's disease, Mild Cognitive Impairment and treatment-resistant depression (XPro). The NK Cell Priming Platform includes INKmune developed to prime a patient's NK cells to eliminate minimal residual disease in patients with cancer. Its product platforms utilize a precision medicine approach for the treatment of hematologic and solid tumor malignancies, and chronic inflammation.

Ticker

INMB

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Raymond Tesi

Employees

11

Headquarters

Boca raton, United States

INmune Bio Metrics

BasicAdvanced
$187M
Market cap
-
P/E ratio
-$1.92
EPS
1.91
Beta
-
Dividend rate
$187M
1.91097
$14.74
$6.50
116K
1.709
25.687
-16.97%
-57.11%
-81.82%
-74.12%
1,427.053
5.845
14.945
-47.39%
-27.66%
142.12%

What the Analysts think about INmune Bio

Analyst Ratings

Majority rating from 3 analysts.
Buy

INmune Bio Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0.00% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$11M
30.95%
Profit margin
0.00%
NaN%

INmune Bio Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 14.02%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.36
-$0.48
-$0.47
-$0.61
-
Expected
-$0.40
-$0.40
-$0.44
-$0.54
-$0.63
Surprise
-9.24%
21.52%
6.82%
14.02%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for INmune Bio stock?

INmune Bio (INMB) has a market cap of $187M as of June 15, 2024.

What is the P/E ratio for INmune Bio stock?

The price to earnings (P/E) ratio for INmune Bio (INMB) stock is 0 as of June 15, 2024.

Does INmune Bio stock pay dividends?

No, INmune Bio (INMB) stock does not pay dividends to its shareholders as of June 15, 2024.

When is the next INmune Bio dividend payment date?

INmune Bio (INMB) stock does not pay dividends to its shareholders.

What is the beta indicator for INmune Bio?

INmune Bio (INMB) has a beta rating of 1.91. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the INmune Bio stock price target?

The target price for INmune Bio (INMB) stock is $19.67, which is NaN% below the current price of $. This is an average based on projections from 3 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell INmune Bio stock

Buy or sell INmune Bio stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing